Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Among all the different types, non-small cell lung cancer (NSCLC) accounts for 80–85% and most patients (70%) are diagnosed at advanced disease (1). In the last decade, targeted therapies for patients with epidermal growth factor receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) or ROS1 rearrangements, together with immunotherapy have modified therapeutic landscape in metastatic NSCLC (2).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
